Table 1.
Characteristics of the study sample including ineligible individuals.
| Characteristics | Total |
Seropositivity |
|||
|---|---|---|---|---|---|
| Missing data | n = 1077 |
Negative |
Positive |
P valuea | |
|
(n = 378) |
(n = 687) |
||||
| n (%) | n (%) | ||||
| Sex | 0 | 0.200 | |||
| Female | 786 (66.7%) | 268 (30.2%) | 514 (69.8%) | ||
| Male | 291 (33.3%) | 110 (35.5%) | 173 (64.5%) | ||
| Age (years) | 0 | <0.001 | |||
| Mean (SD) | 45.1 (11.8) | 47.6 (11.7) | 43.9 (11.7) | ||
| Median (p25-p75) | 0 | 44.9 (35.0–55.0) | 49.0 (36.0–57.7) | 42.0 (35.0–52.0) | |
| Range (minimum-maximum) | 24.0–70.0 | 25.0–69.0 | 24.0–70.0 | ||
| Age | 0 | 0.004 | |||
| 18 to 44 | 500 (49.8%) | 150 (25.7%) | 345 (74.3%) | ||
| 45 to 59 | 395 (34.1%) | 152 (37.0%) | 237 (63.0%) | ||
| 60 or more | 182 (16.1%) | 76 (40.5%) | 105 (59.5%) | ||
| Nationality | 0 | 0.018 | |||
| Peruvian | 1069 (99.6%) | 377 (32.0%) | 680 (68.0%) | ||
| Foreign | 8 (0.4%) | 1 (4.7%) | 7 (95.3%) | ||
| Comorbidities | 10 | 0.300 | |||
| None | 720 (69.6%) | 250 (30.5%) | 465 (69.5%) | ||
| One | 266 (24.2%) | 92 (35.0%) | 169 (65.0%) | ||
| Two or more | 81 (6.2%) | 34 (40.8%) | 45 (59.2%) | ||
| Previous SARS-CoV-2 infection | 4 | <0.001 | |||
| No | 651 (58.5%) | 344 (49.7%) | 297 (50.3%) | ||
| Yes | 422 (41.5%) | 34 (7.5%) | 386 (92.5%) | ||
| Profession | 0 | <0.001 | |||
| Physician | 289 (16.0%) | 130 (45.4%) | 151 (54.6%) | ||
| Administrative or other | 283 (45.3%) | 103 (32.3%) | 177 (67.7%) | ||
| Nurse | 284 (25.9%) | 100 (31.7%) | 183 (68.3%) | ||
| Nursing technician | 221 (12.9%) | 45 (14.7%) | 176 (85.3%) | ||
| Work modality | 1 | 0.002 | |||
| Non-attendance | 137 (11.9%) | 65 (46.1%) | 71 (53.9%) | ||
| Face-to-face | 866 (82.1%) | 278 (29.0%) | 577 (71.0%) | ||
| Mixed | 38 (3.2%) | 22 (55.8%) | 16 (44.2%) | ||
| Licensed | 35 (2.8%) | 12 (29.0%) | 23 (71.0%) | ||
| Work area | 0 | 0.076 | |||
| Hospitalization/Surgery | 226 (46.9%) | 67 (29.2%) | 155 (70.8%) | ||
| Administrative or other related | 151 (11.3%) | 56 (32.8%) | 95 (67.2%) | ||
| Diagnostic support and other related | 145 (12.3%) | 54 (37.9%) | 88 (62.1%) | ||
| Outpatient, extramural and other related | 191 (8.3%) | 81 (45.2%) | 107 (54.8%) | ||
| Critical care | 185 (6.2%) | 69 (35.7%) | 116 (64.3%) | ||
| Emergency or urgent care | 179 (15.0%) | 51 (26.1%) | 126 (73.9%) | ||
| Main work area | 66 | 0.034 | |||
| ICU | 167 (8.8%) | 54 (26.4%) | 112 (73.6%) | ||
| Emergency | 174 (16.9%) | 43 (22.5%) | 127 (77.5%) | ||
| Hospitalization | 212 (28.7%) | 59 (27.6%) | 153 (72.4%) | ||
| Non-COVID-19 Clinic | 89 (5.1%) | 32 (41.5%) | 55 (58.5%) | ||
| Home care | 10 (2.6%) | 5 (36.3%) | 5 (63.7%) | ||
| Administrative care | 61 (7.6%) | 26 (37.3%) | 34 (62.7%) | ||
| Research | 1 (0.0%) | 1 (100.0%) | 0 (0.0%) | ||
| Remote work | 86 (7.7%) | 45 (52.3%) | 40 (47.7%) | ||
| Other | 211 (22.6%) | 85 (34.6%) | 124 (65.4%) | ||
| Works in COVID-19 area | 40 | 0.002 | |||
| No | 527 (50.9%) | 205 (36.8%) | 317 (63.2%) | ||
| Yes | 510 (49.1%) | 154 (24.5%) | 349 (75.5%) | ||
| EsSalud hospital of work | 0 | 0.600 | |||
| I Octavio Mongrut Muñoz Hospital | 52 (4.5%) | 18 (40.7%) | 34 (59.3%) | ||
| Alberto Sabogal Sologuren National Hospital | 341 (23.3%) | 128 (33.4%) | 212 (66.6%) | ||
| Edgardo Rebagliati Martins National Hospital | 465 (42.3%) | 156 (31.3%) | 308 (68.7%) | ||
| Guillermo Almenara Irigoyen National Hospital | 198 (24.3%) | 70 (32.5%) | 118 (67.5%) | ||
| Villa Panamericana | 21 (5.5%) | 6 (20.5%) | 15 (79.5%) | ||
| BBIBP-CorV doses | 0 | 0.070 | |||
| One dose | 17 (2.4%) | 1 (7.9%) | 16 (92.1%) | ||
| Two doses | 1060 (97.6%) | 377 (32.5%) | 671 (67.5%) | ||
| Additional vaccination abroad | 0 | 0.150 | |||
| No | 1071 (99.6%) | 378 (32.0%) | 681 (68.0%) | ||
| Yes | 6 (0.4%) | 0 (0.0%) | 6 (100.0%) | ||
| Time since first dose (days) | 3 | 0.130 | |||
| Median (p25-p75) | 152.0 (145.0–155.0) | 153.0 (145.0–155.0) | 152.0 (145.0–155.0) | ||
| Range (minimum-maximum) | 13.0–163.0 | 95.0–163.0 | 13.0–163.0 | ||
| Time since second dose (days) | 19 | 0.033 | |||
| Median (p25-p75) | 130.0 (124.0–134.0) | 131.0 (124.0–134.0) | 130.0 (123.0–134.0) | ||
| Range (minimum-maximum) | 14.0–142.0 | 14.0–142.0 | 14.0–142.0 | ||
n: unweighted absolute frequency; %: weighted percentage; ICU: intensive care unit; SD: standard deviation.
*Ineligible individuals were those who had only one dose of vaccine, were vaccinated with a vaccine other than BBIBP-CorV and/or were vaccinated abroad. Likewise. we also excluded those who did not have complete data on the response variable.
a
Squared chi-square test with Rao and Scott second-order correction; Wilcoxon rank sum test for complex samples.